Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by Noloon Jun 12, 2019 6:34am
230 Views
Post# 29817505

Email from Oncore

Email from OncoreHey guys. I wrote Oncore immediately after finding their website, wednesday, and Martin Verronneau answered my email this morning (this is genuine, by the way. I'm not trying to lure anyone. I just want to share): 

'Thank you for reaching out to us during these exciting times. We are and have been working on distribution agreements around the world and you will be hearing from our company and our positioning very soon.
 
We are working on releasing our complete web platform by the end of this month and further information on our team, and partners.
 
As per our financing plans and our "go public" strategy; we are currently doing a Series A financing for 1.5 million shares at a price of $1.00 with a warrant at $3.00 (24 months)  at a pre-money valuation of $10 million, and it will be followed by a round of 1 million shares at $3.00 with a 1/2 warrant at $5.00 (12 months) and our last round prior to listing will be a Regulation A+ financing for 2 million shares at $5.00 with 1/2 warrant at $7.50 (6 months). 
 
We are working with Wynston Hill Capital and Network 1 to complete the Reg A+ and the listing of the company on NASDAQ. 
 
I hope this answers your inquiry and we look forward to any questions and or comments.
 
Thanks,
 
Martin Verronneau, BS, CCPE
President, COO & Co-Founder'


So, we have a part of the answer but a lot remains to be known, like for example, on how they are going to pull it off in Europe and elsewhere. More details to come as soon as I get them. 
Bullboard Posts